Pricing Log in Create free account

AbCellera Biologics Inc. (ABCL) vs Relay Therapeutics, Inc. (RLAY)

AbCellera Biologics Inc. and Relay Therapeutics, Inc. are both Biotechnology companies. AbCellera Biologics Inc. and Relay Therapeutics, Inc. are of similar size ($4.1B and $3.8B). AbCellera Biologics Inc. grew revenue faster over the last twelve months: 101.3% against −74.3%. AbCellera Biologics Inc. has the higher net margin (−248.8% vs −2,594.2%) and the lower return on invested capital (−42.5% vs 0.00%). Across the 16 metrics below, AbCellera Biologics Inc. leads on 11 and Relay Therapeutics, Inc. on 5.

Valuation

Metric ABCL RLAY Biotechnology median
P/E n/m n/m 8.50
P/S 54.49 299.51 9.71
P/B 4.02 3.71 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 46.00 216.89 9.21
Earnings yield (4.58%) (9.64%) (33.15%)
Free cash flow yield (3.41%) (6.44%) (25.50%)

Profitability

Metric ABCL RLAY Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (340.25%) (2,815.49%) 0.00%
Net margin (248.82%) (2,594.20%) 0.00%
Free cash flow margin (180.84%) (1,924.59%) 0.00%
Return on equity (17.30%) (36.77%) (56.36%)
Return on assets (12.15%) (33.72%) (48.04%)
Return on invested capital (42.52%) 0.00% 0.00%

Growth

Metric ABCL RLAY Biotechnology median
Revenue growth (TTM) 101.29% (74.29%) 6.02%
EPS growth (last fiscal year) 10.91% 31.78% 30.26%
Revenue growth, 5-year CAGR (20.27%) (28.58%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABCL RLAY Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.77 18.27 4.72
Net debt to EBITDA 2.97 1.84 0.96

Dividend

Metric ABCL RLAY Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ABCL RLAY Biotechnology median
Market cap 4.11b 3.79b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack